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Abstract
Background: Inflammatory and degenerative activity inside the joint can be studied in vivo via analysis of synovial
fluid (SF) biomarkers, which are molecular markers of inflammatory processes and tissue turnover. The aim of this
study was to investigate the response of selected biomarkers in the SF after an intra-articular (IA) high-molecular-
weight non-animal stabilized hyaluronic acid (NASHA) treatment. Our hypothesis was that prostaglandin E2 (PGE2),
substance P, aggrecan chondroitin sulfate 846 epitope (CS846), and carboxypeptide of type II collagen (CPII)
concentrations in SF would decrease more in the NASHA than in the placebo group. Twenty-eight clinically
lame horses with positive responses to diagnostic IA anaesthesia of the metacarpophalangeal or metatarsophalangeal
joints were randomized into treatment (n = 15) and control (n = 13) groups. After collection of baseline SF samples
followed by IA diagnostic anaesthesia, horses in the treatment group received 3 ml of a NASHA product IA. Those in
the placebo group received an equivalent volume of sterile 0.9% saline solution. The horses were re-evaluated and a
second SF sample was obtained after a 2-week period.
Results: CS846 concentration decreased in the NASHA group only (P = 0.010). Both PGE2 and CPII concentrations
decreased within the groups (PGE2, P = 0.010 for the NASHA group; P = 0.027 for the placebo group; CPII, P < 0.001 for
NASHA group; P = 0.009 for placebo group). No significant treatment effect for any biomarker was found between
groups. NASHA induced an increase in white blood cell count; this was significant compared with baseline (P = 0.021)
and the placebo group (P = 0.045).
Conclusions: Although the SF concentration of the cartilage-derived biomarker CS846 decreased in the NASHA group,
no statistically significant treatment effect of any of the biomarkers were observed between treatment groups. The
significant increase in SF white blood cell count after IA NASHA may indicate a mild inflammatory response. However,
as no clinical adverse effects were observed, we conclude that IA NASHA was well tolerated.
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Background
A majority of athletic horses suffer from lameness dur-
ing their careers. Lameness resulting from joint disease
is one of the major causes of poor performance [1, 2].
Intra-articular (IA) hyaluronan (HA) injection is a com-
monly used treatment for equine synovitis and osteo-
arthritis (OA), although only a few clinical studies have
been conducted on IA HA treatment without any other
medication in horses [3–7]. Hyaluronan is a glycosamino-
glycan component of the synovial fluid (SF) and proteogly-
can aggregates in the articular cartilage. The complete
mechanism of HA action is not yet fully understood. HA
reduces the sensitivity of articular nerve endings in the
joint capsule by buffering transmission of mechanical
forces to nociceptor nerve endings and thereby reduces
pain [8]. HA also reduces impulse activity in the periph-
eral nociceptor endings by affecting receptor channels [9].
Furthermore, HA has an anti-inflammatory effect [8, 10–
12]. However, repeated IA HA injections have also been
found to induce a transitional IA inflammation reaction
first [13–15], likely caused by low molecular weight break-
down products of HA [14].
Inflammatory and degenerative activity inside the joint
can be studied in vivo via analysis of SF biomarkers,
which are molecular markers of inflammatory processes
and tissue turnover. Research into the biomarkers of
equine SF has been focused on finding tools for early
diagnosis and monitoring the progression of OA [16–
21]. Furthermore, equine SF biomarkers have been used
to measure responses to treatments [22, 23] and to
evaluate any possible deleterious effects of IA medica-
tions [24, 25] and autologous platelet-rich plasma [26].
The aim of this study was to measure SF prostaglan-
din E2 (PGE2), substance P, aggrecan chondroitin sul-
fate 846 epitope (CS846), and carboxypeptide of type II
collagen (CPII) concentrations before and 2 weeks after
high-molecular-weight non-animal stabilized hyalur-
onic acid1 (NASHA) or placebo (saline) injections in
horses suffering clinically from pain in the metacarpo-
phalangeal or metatarsophalangeal joints.
Prostaglandin E2 (PGE2) was chosen since it is the most
important eicosanoid in joint diseases. Elevated SF PGE2
levels and increased lameness in horses have been shown
in several experimental studies after induction of synovitis
or OA [23, 27–29]. Substance P is a pro-nociceptive
neuropeptide [30] that has been shown to increase in
osteoarthritic equine joints [21]. Furthermore, a relation-
ship between elevated SF substance P concentration and
pain and lameness in horses has been reported [31]. In the
present study, substance P was chosen because in the first
part of the study [32] joint pain and lameness and their re-
sponse to NASHA1 and placebo injections were examined.
The marker of collagen II synthesis has been shown to
increase for a prolonged period in the SF of the
LPS-induced synovitis model [28]. In contrast to that
model and induced OA [17], joint pain was not related
to SF CS846 or CPII and cartilage turnover in clinical
patients [31]. However, CS846 and CPII were chosen as
cartilage turnover markers for the present study.
In contrast with the short half-life of commonly used
unmodified HA preparations [33, 34], NASHA has a
long half-life (up to 32 days) [35] and remains in the
synovial structures for a considerably longer period than
other HA products [36–38]. This medication is thus
intended for treating human arthritic conditions and po-
tentially has a long-acting clinical effect on relieving pain
and inflammation [39]. The pain-relieving effects of
NASHA were also recently investigated clinically in lame
horses [32]. Our hypothesis was that the decrease of se-
lected SF biomarker concentrations would be greater in
the NASHA group horses compared with the placebo
group horses.
Methods
Horses were presented to the University of Helsinki Veter-
inary Teaching Hospital for the NASHA study. The study
was approved by the Viikki Campus Research Ethics Com-
mittee of the University of Helsinki. All horse owners
signed a study consent before the start of the study and
owners were allowed withdraw from the study without
giving any particular reason. Twenty-eight horses were in-
cluded in the present trial.
The NASHA study was performed as a randomised
double-blind and placebo-controlled trial with a parallel
group design and equal allocation ratio [40]. Before
starting the study, a non-blinded assisting technician
created a computer-generated randomization list. Horses
fulfilling the inclusion criteria were assigned to the treat-
ment (NASHA) or control group according to the
randomization list. The list and the NASHA1 and pla-
cebo products were kept in a locked safe that only the
non-blinded assisting veterinarian and the associated
technician could access. The NASHA study was planned
according to the CONSORT statement and the results of
the clinical study have been reported earlier [32].
Horses with lameness due to synovitis of the metacar-
pophalangeal or metatarsophalangeal joint with or with-
out mild OA and a positive response to diagnostic IA
anaesthesia of the affected metacarpophalangeal or
metatarsophalangeal joint but with no radiographic signs
of OA (subchondral bone lucency or sclerosis, peri-
articular osteophyte formation, or narrowing of the joint
space) of the affected joint were included in the study.
Horses with severe or chronic OA were excluded. Mild
remodelling of the joint and synovitis of all durations
were acceptable. Adult, non-geriatric (age between 4 and
17 years), Finnhorse, Standardbred, Warmblood horses
as well as large ponies (height 140–148 cm) of all
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disciplines were eligible. The ponies are referred to as
horses in the text. In addition, horses with IA osteo-
chondral or other fragments were excluded. Bilaterally
lame horses and horses that had received IA medications
(such as corticosteroids or HA within the previous
3 months or peroral NSAIDs within 15 days) were not
eligible. Furthermore, horses with concurrent patholo-
gies (such as clinically significant ligament, tendon, or
other soft tissue injuries in the affected limb) were ex-
cluded. Treatment groups were equal at the first clinical
(baseline) examination; no statistically significant differ-
ence between the two groups was found in signalment,
use of the horse, radiograph findings, or clinical outcome
measures. These measures included lameness, effusion of
the affected joint, flexion test result, or pain in flexion.
The pain score was created by the authors and recorded
as follows: 0 = no pain on flexion, 1 =mild pain (i.e., the
horse shows some reaction, such as moving the limb), 2 =
moderate pain (i.e., the horse retracts the limb repeatedly
during the 1-min flexion period), 3 = severe pain (i.e., the
flexion test cannot be properly performed) [32].
The previously published clinical section [32] of the
NASHA study provides more detailed data of the study
population. Horses were subjected to a full lameness
examination and radiographic examination of the affected
joint with four standard views as described [32]. Prior to
IA anaesthesia (mepivacaine hydrochloride2) of the meta-
carpophalangeal or metatarsophalangeal joint, which was
performed to localize the source of lameness and to de-
cide if the horse was eligible for the study (80–100%
amelioration of lameness), 5 ml of SF was aspirated into a
sterile 5-ml syringe for biomarker measurements. Arthro-
centesis was performed through the lateral sesamoidean
ligament and blood contamination was recorded if ob-
served in the SF sample. The SF sample was immediately
divided into a plain tube on ice (4 ml) and an EDTA
(1 ml) tube. White blood cell (WBC) count and protein
concentration measurements were performed from the
fresh sample in the EDTA tube. Within 1 h of collection,
the plain sample was centrifuged at 1700 g for 10 mins in
4 °C, after which it was aliquoted and stored at − 80 °C. If
the horse fulfilled the inclusion criteria after examination,
the horse received IA NASHA1 (3 ml, 20 mg/ml into the
affected joint) or an IA placebo injection (3 ml of a sterile
0.9% saline solution3) on the same day by the non-blinded
assisting veterinarian. The horse was then sent home with
the owner and asked to return in 2 weeks, when it was
subjected to a second clinical examination [32]. Following
the first clinical examination and treatment, the horse was
allowed 30 min hand-walking per day and free access to a
small paddock during the 2 weeks, after which the second
clinical examination was performed and a second SF sam-
ple (5 ml) was collected and processed using the same
techniques as described above.
SF samples were digested with 0.5 mg/ml hyaluroni-
dase from bovine testes for 30 min at 37 °C prior to ana-
lyses of SF PGE2, substance P, CS846, and CPII.
Prostaglandin E2
Prostaglandin E2 was measured using a commercial en-
zyme immunoassay kit.4 Sample extraction was per-
formed according to the manufacturer’s instructions
prior to the immunoassay. Briefly, SF samples were acid-
ified by the addition of 1 M hydrochloric acid to pH 3.5
and then vortexed and centrifuged for 2 min at 12000 ×
g. The samples were applied to a C18 cartridge5 previ-
ously conditioned with ethanol and water, and then
flushed with water, 15% ethanol, and finally with hexane.
PGE2 was eluted from the cartridge with ethyl acetate
and stored as an elution solution at − 80 °C until ana-
lysis. The extracted samples were analysed within 1 week.
At the time of the assay, the samples were evaporated to
dryness in a vacuum evaporator and reconstituted with
assay buffer and analysed according to the manufac-
turer’s instructions. The samples were extracted and
analysed in duplicate. Parallelism was tested for dilutions
between 1:2 and 1:50. An appropriate dilution was made
for every sample. The detection range was 7.81 to
1000 pg/ml with a detection limit of 11 pg/ml. Recovery
of the extraction was 81 to 114%. The intra-assay coeffi-
cient of variation (CV) was 14.6%.
Substance P
Substance P was measured using a commercial enzyme
immunoassay kit6 according to the manufacturer’s in-
structions. Samples were analysed in duplicate. The de-
tection range was 3.9 to 500 pg/ml with a detection
limit of 10.5 pg/ml. The intra-assay CV was 12.5%.
Aggrecan chondroitin sulfate 846 epitope
CS846 epitope was measured using a commercial en-
zyme immunoassay kit7 according to the manufacturer’s
instructions. The samples were then diluted 1:50 and
added to plates in triplicate. The result was reported as
the mean of triplicate values, unless the CV was over
20%; in this case the mean of the two closest values was
calculated. The detection range was 20 to 1000 ng/ml
with a detection limit of 20 ng/ml. The intra-assay CV
was < 20%.
CPII
CPII was measured using a commercial enzyme im-
munoassay kit8 according to the manufacturer’s instruc-
tions. The samples were diluted 1:5 and added to plates
in duplicate. The detection range was 50 to 2000 ng/ml
with a detection limit of 50 ng/ml. The intra-assay CV
was 8.1%.
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Statistical methods
A sample size calculator [40] was used with 95% confi-
dence level and 80% power. On the basis of 87% of cases
showing clinical improvement in an earlier study on HA
for the treatment of naturally occurring arthritic condi-
tions in horses, the estimated sample size was 11 to 14
horses per group [5]. In the placebo group, the proportion
that would improve was considered to be 20 to 30%,
where 20% is 10% lower than the percentage that has been
used in placebo groups in human studies [41, 42].
SF biomarker (substance P, CPII, PGE2, CS846) con-
centrations, WBC count, and protein concentration
measurements were analysed with analysis of covariance
models. Changes between the baseline and follow-up
measurements were used as the response, treatment was
used as the fixed effect, and the corresponding baseline
measurement as the covariate. For SF concentrations of
substance P and CPII and SF WBC count, a logarithmic
transformation was used to normalize the distributions.
For PGE2 concentration an inverse transformation was
used to normalize the distributions. CS846 and TP were
normally distributed.
The possible effects of background variables (age, gen-
der, breed, use of the horse, lameness score, duration of
clinical signs, previous incidences of the affected joint,
radiograph findings) on the change in the different bio-
marker measurements from baseline were assessed with
analysis of variance models. The models included the
background variable of interest as the sole fixed effect
and the change of the biomarker from the baseline as
the response. If some of the background variables were
statistically significant in these analyses, the effect was
also included in the analysis of covariance model for
treatment comparison.
We hypothesized that the decrease of these SF bio-
marker concentrations would be greater in the NASHA
group than that of the placebo group. The difference in
the change of each SF biomarker concentration after IA
injection and a two-sided 95% confidence interval for
the difference were estimated from the fitted analysis of
covariance models using the contrast method. The esti-
mates of the changes within groups were also calculated.
Significance was set at P < 0.05 for all analyses. The same
statistical analysis software9 was used for all statistical
analyses.
Results
Sixty-eight horse owners were interviewed; 36 horses
were invited to the first clinical baseline examination.
Altogether 30 horses fulfilled the inclusion criteria. Two
horses were excluded due to an inadequate amount of
high-quality SF for baseline and control samples; 28
horses were thus included in the study. The median age
of the horses was 7 years in the NASHA (n = 15) and
placebo (n = 13) groups (range 4–12 and 4–17 years, re-
spectively). There were seven mares, five geldings, and
three stallions in the NASHA group. There were six
mares, five geldings, and two stallions in the placebo
group. Of the horses in the NASHA group, 10 were har-
ness racehorses and five were riding horses predomin-
ately used for general-purpose riding. In the placebo
group there were seven harness racehorses and six riding
horses. The breeds in the NASHA group were Finnhorse
(n = 8), Standardbred (n = 6), and Warmblood (n = 1).
The breeds in the placebo group were Finnhorse (n = 5),
Standardbred (n = 4), Warmblood (n = 2), and pony (n =
2). At the first examination, the source of lameness was
localized to the right metacarpophalangeal joint in 10
(NASHA group) and seven horses (placebo group), to
the left metacarpophalangeal joint in four (NASHA
group) and six horses (placebo group), and to the left
metatarsophalangeal joint in one horse (NASHA group).
No adverse effects of IA NASHA or placebo injections
were observed at the second clinical examination or re-
ported by the horse owners.
Background variables (age, gender, breed, use of the
horse, lameness score, duration of clinical signs, previous
incidences of the affected joint, radiograph findings) did
not have any effect on the concentration changes of the
different biomarkers.
NASHA induced a significant increase in SF WBC
count when compared with baseline (P = 0.021) and the
placebo group (P = 0.045) (Fig. 1). When the change in
SF biomarker concentrations was compared between
groups, no significant difference was detected (PGE2, P
= 0.768; substance P, P = 0.662; CS846, P = 0.207; CPII, P
= 0.155) (Fig. 1). When examining SF biomarkers within
groups, both PGE2 and CPII concentrations decreased
(PGE2, P = 0.010 for the NASHA group; P = 0.027 for
the placebo group; CPII, P < 0.001 for NASHA group; P
= 0.009 for placebo group) (Fig. 1). However, for SF
CS846 concentration, a statistically significant reduction
from baseline was seen in the NASHA group (P = 0.010)
but not in the placebo group (P = 0.390) (Fig. 1).
Discussion
In this study, the SF concentrations of selected bio-
markers were measured before and 2 weeks after IA
NASHA treatment in horses with lameness localized to
the metacarpophalangeal or metatarsophalangeal joint.
IA NASHA caused an increase in SF WBC count.
Blood contamination during sampling is an unlikely ex-
planation since the arthrocentesis was performed
through the lateral sesamoidean ligament, which has
been shown to induce less synovial haemorrhage than
arthrocentesis through the proximal palmar pouch [43].
In addition, no blood contamination in the analysed SF
samples was observed. It seems more likely that IA
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injection of NASHA induces a mild inflammatory re-
sponse; this has also been reported after a combined in-
jection of IA pentosane polysulfate and glucosamine
injection [44], after repeated IA amikacin injection [45],
and after IA gentamicin injection [46]. Moreover, arthro-
centesis alone [46] and IA saline injection [44, 45] have
been shown to cause significant increases in the SF
WBC count. In humans, a transient IA inflammation
has been reported after consecutive HA injections [13–
15], likely caused by a cell-mediated hypersensitivity re-
action [15] to the low-molecular-weight breakdown
products of HA [14]. However, in the present study, no
clinical signs (such as effusion or pain in the injected
joint) were reported by the horse owners or trainers im-
mediately after the injection. Moreover, in most of the
samples the increased WBC count was within the nor-
mal reference range (< 0.5 × 109/l) or very close (< 1.0 ×
109/l) [47]. One explanation for the difference in the
Fig. 1 Synovial fluid white blood cell count (a), concentrations of total protein (b), prostaglandin E2 (outliers > 1000 pg/ml are removed to clarify
figure) (c), substance P (d), aggrecan chondroitin sulfate 846 epitope (e) and carboxypeptide of type II collagen (f) before and after intra-articular
NaCl (placebo) or non-animal stabilized hyaluronic acid (NASHA) injection. First and third quartiles are defined by the boxes and median by the
band inside. The 2.5th and the 97.5th percentiles are shown as the lower and upper whiskers. *P < 0.05, **P < 0.001 between first and second
sample in NaCl (placebo) and NASHA group respectively, † P < 0.05 NaCl (placebo) and NASHA groups
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WBC count between groups could be decreased SF vol-
ume after NASHA injection, although no difference in
the joint effusion score between groups was found [32].
When compared with the placebo group, the NASHA
injection had no significant effect on SF PGE2 concen-
tration. The effect of various substances on PGE2 con-
centration in equine SF has been evaluated previously
mainly in experimental studies using induction models
[22, 23, 27–29] or horses free of lameness or joint dis-
ease [24]. Only Carmona et al. [48] have studied SF
markers and their response to treatment in clinical
equine patients. As in the present study, they did not
find a significant decrease between groups in the SF
PGE2 concentration when an oral HA formulation was
evaluated in horses suffering from osteochondrosis.
PGE2 concentration has been shown to increase in SF of
equine osteoarthritic joints [19, 21]. Bertone et al. [18] re-
ported SF PGE2 concentration to be a good or excellent
predictor of joint disease and thus a functional screening
test tool in horses. However, high variability in concentra-
tions limited discrimination among the types of joint dis-
ease. In contrast, Frisbie et al. [49] speculated that SF
PGE2 concentration may not be a true indicator of overall
joint health, as no remarkable disease-modifying effects
were detected after phenylbutazone treatment in their ex-
perimentally induced equine OA model despite decreased
PGE2 concentration. In the present study, we were unable
to observe significantly decreased SF biomarker concen-
trations in the NASHA group compared with placebo.
This may be a result of high variation in concentrations
initially, and more specifically, high variations in responses
to the treatment. In the case of synovitis, PGE2 concentra-
tion may decrease more rapidly than in mild OA. Frisbie
et al. [17] showed that there is a long-standing increase in
PGE2 concentration after arthroscopically induced OA
while the increase was short-term in other studies using
the LPS inflammation induction model [28, 29]. However,
the lack of treatment effect by HA on SF PGE2 concentra-
tion was also reported in experimental studies with more
uniform osteoarthritic joints [12, 22]. Another study by de
Grauw et al. [31] concluded that PGE2 concentration
might reflect joint pathology in general rather than specif-
ically pain arising from the joint.
In the present study, no differences in SF substance P
concentrations were observed within or between treat-
ment groups. This is in contrast with the reported ele-
vated concentrations in SF from osteoarthritic joints
compared to normal equine joints [21]. Substance P con-
centration has been shown to be associated with joint pain
[31]. In the equine LPS-induced synovitis model, sub-
stance P decreased following meloxicam treatment [28]
but not after IA opioid analgesia [23]. Both medications
resulted in decreased lameness. The differences in re-
sponses after the aforementioned medications can be
explained by different mechanisms of action (i.e., opioid
analgesia has presynaptic control while NSAIDs influence
the release of substance P) [28, 31]. The complete mech-
anism of action of HA in the joint is not known but it has
been shown that HA reduces the sensitivity of articular
nerve endings by buffering transmission of mechanical
forces to nociceptor nerve endings [8] and by affecting
pain receptor channels [9]. The binding of neuropeptides
could be one pain-reducing mechanism of HA. The re-
sults of the present study suggest, however, that intrasyno-
vial NASHA injections do not have an effect on SF
substance P concentration. The clinical section of this
NASHA study showed reduction in pain sensation, as
horses had a statistically milder response in the flexion
test after they had received an IA NASHA injection [32].
This may be due to reducing sensitivity of nerve endings
by the aforementioned mechanisms. However, the lame-
ness score was not significantly different between the
NASHA and placebo groups [32].
Frisbie et al. [17] showed a significant increase of SF
CS846 and CPII concentrations in horses with induced
OA compared to exercise-only horses. Although the
change in SF CS846 concentration was not different be-
tween the treatment groups, the concentration de-
creased in the NASHA group after the IA injection in
the present study. CS846 concentration has been shown
to increase in SF following naturally occurring injury
and OA in humans [50] and after surgically induced OA
[51] and LPS-induced synovitis [52] in horses. Further-
more, exercise induces elevation of SF CS846 concentra-
tion in horses [17].
CS846 levels were reported to have a significant correl-
ation with CPII [17]. However, such a correlation was not
shown when the effects of meloxicam on cartilage turn-
over was studied in the equine LPS-induced synovitis
model. While no treatment effect was seen on CS846 epi-
tope levels, CPII concentration was significantly reduced
compared to placebo [28]. In addition, phenylbutazone
has been shown to reduce CPII levels in a comparable
equine model [53]. Along with the increase of CPII, an in-
crease in CS846 after IA lidocaine and bupivacaine injec-
tions in healthy equine joints was speculated to be the
reparative response to the short chondrotoxic effect of
these compounds [24]. As IA mepivacaine was injected on
the same day (NASHA was also injected on the same
day), it is possible that this IA anaesthetic was interfering
with the biomarker concentrations to some extent. IA
methylprednisolone was reported to elevate CS846 in
horses free of joint disease, which suggests an increase in
articular matrix turnover [25].
The cause for the decrease in CPII is unclear. SF CPII
concentration decreased in both groups compared with
pre-injection samples. Although the decrease could be
interpreted as impaired synthesis of type II collagen, it
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may also reflect the fact that less damage to collagen has
occurred in the joint after medication [28]. Unfortu-
nately, the collagen degradation marker C2C was not
measured in the present study to demonstrate this. It
has been shown that CPII increases in equine joints after
different types of insults, such as after LPS injection in
the normal equine intercarpal joint [52] and after exer-
cise or surgically induced OA [17]. The decreasing con-
centrations of SF CPII after IA injections in the present
study could indicate compromised synthesis of type II
collagen. This may also indicate less degradation of car-
tilage after the horses had discontinued training and
rested due to participating in the study.
A 2-week period between SF sampling was chosen to
optimize the clinical action of the NASHA injection
[32]. The maximum effect of pain reduction of IA HA
injection has been shown to be between 2 to 6 weeks
post-treatment [7, 39]. On the other hand, some of the
SF markers could have returned to baseline even earlier
regardless of NASHA or saline injection. In the equine
LPS induction model, PGE2 and CS846 were reported
to return to the baseline level before or at 168 h
post-injection, while CPII stayed above the baseline
level after that [52]. However, since our study popula-
tion consisted of client-owned patients and many had
to travel a long distance to the hospital, it was logistic-
ally difficult to organize additional SF sampling visits,
either between the baseline and the final samplings or
after 2 weeks. Frequent sampling of the SF also induces
articular inflammation and therefore has an effect on
the measured parameters, which would make assess-
ment of these results challenging.
The absence of significant differences in the SF
markers between groups could due to the wide varia-
tions in concentrations within groups. The intra-assay
CV was also relatively high in some analyses (> 10% for
PGE2, substance P, and CS846). The disease stage and
the intensity of inflammation influence concentrations
of cartilage-derived markers [54]. Furthermore, time and
type of primary insult, duration of lameness, disease, and
the extent of joint effusion may have an effect on the SF
concentrations of different markers. However, these vari-
ables were controlled as best as possible in the present
study, as the demographic and clinical variables were
similar between the treatment groups [32]. Also, demo-
graphic and clinical variables had no effect on the SF
biomarker concentrations. Despite these precautions, in-
flammation may have been more acute and cartilage
matrix degradation more advanced in some of the joints.
The high variation in the initial SF baseline biomarker
concentrations reflects this. Therefore, although we had
calculated the group size according to previous studies,
a much larger sample size is necessary to show possible
differences between the groups.
Conclusions
Although cartilage-derived biomarker CS846 concentra-
tions in SF decreased only in the NASHA group, no sta-
tistically significant change of any of the biomarkers was
observed between the two treatment groups in this
study. The IA NASHA injection induced significant in-
crease in SF WBC count; this may indicate an inflamma-
tory response akin to that also reported in human
studies. However, IA NASHA injection was well toler-
ated, as no clinically adverse effects were observed.
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